# **SCS** in Itch

No registrations found.

**Ethical review** Positive opinion

**Status** Pending

Health condition type -

Study type Interventional

## **Summary**

#### ID

NL-OMON23833

**Source** 

NTR

**Brief title** 

SCS in Itch

**Health condition** 

Not applicable

### **Sponsors and support**

**Primary sponsor:** Erasmus University Medical Centre **Source(s) of monetary or material Support:** None

### Intervention

#### **Outcome measures**

### **Primary outcome**

VAS for itch.

### **Secondary outcome**

Size of flare, character and constancy of itch.

## **Study description**

### **Background summary**

Electrical neuromodulation therapies such as transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS) and dorsal root ganglion stimulation (DRGS) have earned their place in the treatment of neuropathic pain and are commonly used as a last resort treatment for neuropathic pain. Though it is known that pain and itch are neurologically related phenomena, electrical neuromodulation is far less used in the treatment of itch. Nonetheless, there is evidence that modes of electrical neuromodulation such as TENS are useful in the treatment of itch. We therefore aim to determine whether SCS and/or DRGS can influence the perception of experimentally induced itch.

### Study objective

SCS and/or DRGS alleviates histamine induced itch.

### Study design

Baseline, 15 minutes after histamine application and 1, 5, 10, 15, and 30 minutes after switching on SCS or DRGS.

#### Intervention

Percutaneous administration of a drop of histamine solution to an area innervated by the SCS or DRGS and simultaneous administration of a drop of histamine solution to an area not innervated by the SCS or DRGS.

## **Contacts**

#### **Public**

Erasmus University Medical Centre Moustafa Badwy

010 704 01 40

#### **Scientific**

Erasmus University Medical Centre Moustafa Badwy

010 704 01 40

# **Eligibility criteria**

### Inclusion criteria

Good effect of SCS or DRGS; the area innervated by the SCS or DRGS must extend to a healthy, pain free area of skin; participants must not have objections against switching off his or her SCS or DRGS for up to one hour; age >= 18 years; no ongoing itch perception.

### **Exclusion criteria**

Generalized skin disorder; systemic disease associated with pruritus; complex regional pain syndrome; allergy or hypersensitivity; contra-indications for histamine administration; use of opioids; use of drugs that might potentially prevent the development of a flare.

# Study design

### **Design**

Study type: Interventional

Intervention model: Other

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

### Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-06-2020

Enrollment: 12

Type: Anticipated

### **IPD** sharing statement

Plan to share IPD: Undecided

**Plan description**Not applicable

## **Ethics review**

Positive opinion

Date: 08-05-2020

Application type: First submission

# **Study registrations**

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register ID

NTR-new NL8591

Other METC Erasmus MC: MEC-2020-0241

# **Study results**

#### **Summary results**

None